𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia

✍ Scribed by Charles H. Adler; Stephen F. Bansberg; Kari Krein-Jones; Joseph G. Hentz

Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
68 KB
Volume
19
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

This single‐site, open‐label, dose‐finding study evaluated the safety and efficacy of botulinum toxin type B (BoNT‐B; Myobloc) for the treatment of adductor spasmodic dysphonia (AdSD) in 13 patients. Three patients received a total of 50 U (25 U per vocal fold); the same three subsequently received 100 U, and then 10 more received 200 U. The primary measure of efficacy was the patient's rating of the change in the severity of spasms on a scale from −3 to +3. There were seven secondary measures of efficacy, including blinded ratings of the sound of voice recorded on audiotape. At Week 8 after injection, spasms improved in 0 of 3 patients who received 50 U, 1 of 3 patients who received 100 U, and 8 of 10 patients who received 200 U. The mean (± standard deviation [SD]) score for the change in spasm severity at Week 8 in the 200 U group was 1.4 (±1.2) points (P = 0.004). All seven secondary measures also showed improvement. Breathiness was the most common side effect but was mild in intensity and of short duration. We conclude that BoNT‐B is safe and effective for the treatment of adductor spasmodic dysphonia. © 2004 Movement Disorder Society

📜 SIMILAR VOLUMES

Efficacy and safety of repeated doses of
Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia
✍ Stewart A. Factor; Eric S. Molho; Sharon Evans; Paul J. Feustel 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB

## Abstract Efficacy of botulinum toxin type B (BoNT B) for the treatment of type A‐resistant (AR) and non‐A‐resistant (NAR) cervical dystonia (CD) has been demonstrated in several single injection studies. There is little data available on long‐term therapy with repeated injection sessions and it

Botulinum toxin type B (Myobloc®) in sub
Botulinum toxin type B (Myobloc®) in subjects with hemifacial spasm: Results from an open-label, dose-escalation safety study
✍ Richard M. Trosch; Charles H. Adler; Eric J. Pappert 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB

## Abstract ## Ojbective Evaluate the safety of botulinum toxin type B (BoNT‐B) in subjects with hemifacial spasm (HFS). ## Methods This open‐label, sequential dose‐escalation study evaluated BoNT‐B in subjects with HFS. Eligible subjects were enrolled and received a single injection of one of f

Long-term safety, efficacy, dosing, and
Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia
✍ Brian Berman; Lauren Seeberger; Rajeev Kumar 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 64 KB

## Abstract Short‐term studies of cervical dystonia (CD) have demonstrated botulinum toxin type B (Bot B) to be safe and efficacious at doses of 5,000 to 10,000 units, but few long‐term studies have been published and the safety and efficacy of higher doses has not been established. Additionally, t

BotB (botulinum Toxin type B): Evaluatio
BotB (botulinum Toxin type B): Evaluation of safety and tolerability in botulinum toxin type A-Resistant cervical dystonia patients (preliminary study)
✍ Dr. Daniel D. Truong; Paul A. Cullis; Christopher F. O'Brien; Martin Koller; Tim 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 314 KB

## Abstract Botulinum toxin (BTX) injection is considered the treatment of choice for patients with cervical dystonia (torticollis). We conducted a pilot, open‐label, dose‐escalation study with BTX type B in 12 patients who no longer responded clinically to injections with BTX type A. At the doses

Double-blind, placebo-controlled study t
Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism
✍ Francesca Mancini; Roberta Zangaglia; Silvano Cristina; Maria Grazia Sommaruga; 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB 👁 2 views

## Abstract Drooling is a frequent symptom in Parkinson's disease (PD), occurring in almost 75% of all patients. Although it is now well known that drooling in PD is the result of swallowing difficulties rather than excessive saliva production, few treatments have been developed to reduce it. Clini

Efficacy and safety of botulinum type A
Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: Results of the first US randomized, double-blind, placebo-controlled study
✍ Daniel Truong; Drake D. Duane; Joseph Jankovic; Carlos Singer; Lauren C. Seeberg 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB

## Abstract Botulinum toxin type A (Dysport) has been shown in European studies to be a safe and effective treatment for cervical dystonia. This multicenter, double‐blind, randomized, controlled trial assessed the safety and efficacy of Dysport in cervical dystonia patients in the United States. Ei